The British Medical Association has notified 200 of its 600 England-based staff that their jobs are at risk, according to an exclusive Guardian report from July 4, 2026. The restructuring reveals a long-standing financial problem within the UK's largest doctors' trade union: it cannot cover its own costs from membership fees and services alone.

The paradox is stark. The BMA now has a record 200,000 members but loses millions of pounds annually. Since 2008, the organisation has required £86.8 million in financial support from the British Medical Journal — a publication it owns — just to stay afloat. That averages £5.1 million per year over nearly two decades. Essentially, the BMJ operates as a financial lifeline rather than an independent news operation.

The job cuts are already underway. Industrial relations officer (IRO) positions are being reduced from 23.5 to 14 full-time staff. Three of seven regional heads face elimination. Between 14 and 20 of the 45 people working in the BMA's science and ethics teams are at risk. These are not peripheral roles: IROs represent doctors in NHS workplaces during disputes, grievances, and pay negotiations — the core function of any trade union. Cutting roughly 40% of this capacity will weaken the BMA's ability to support members in local disputes.

The GMB union, which represents most BMA employees, has filed a formal complaint claiming the association broke its own human resources procedures and tried to prevent staff from speaking publicly. BMA employees voted to express no confidence in chief executive Rachel Podolak: 91% voted in favour on a 72% turnout — a result that leaves Podolak without the confidence of her own workforce even as she leads the restructuring. Chairs of 110 local negotiating committees sent a direct letter to Podolak and deputy chair Dr Emma Runswick opposing the IRO and regional head cuts. The BMA's consultants committee passed a separate critical motion on the IRO reductions.

There is a credibility problem. When the Guardian asked about the job losses, the BMA said "as few as 20" would be affected — but the organisation issued formal at-risk notifications to 200 people in consultation with GMB representatives. As of early July 2026, the BMA's public communications pages carried no statement to members about the restructuring, its financial causes, or the job losses. The main messages focused instead on the June 29 announcement that resident doctors had accepted a pay and jobs offer and that strikes would end.

The timing is significant. Resident doctors' ballot papers were submitted days before the staffing crisis became public, following 15 rounds of industrial action and a deal that will set top resident doctor salaries at £77,348. The BMA devoted substantial organisational effort to managing that dispute. The internal restructuring, running in parallel and apparently beginning before the ballot ended, suggests financial pressure has been mounting independently of the union's public disputes with employers.

What emerges is an institution operating a structural deficit that only its ownership of the BMJ has masked. An asset cannot indefinitely absorb losses. The cuts to IROs and regional heads are not minor budget adjustments — they strike at the operational core of how a trade union represents its members. Cutting them while staying silent about the reorganisation is the contradiction that triggered the no-confidence vote and the letter from local negotiating committee chairs.

The BMA has not yet publicly confirmed the full scope of the restructuring, the timeline for final redundancy decisions, or how it plans to reshape its revenue model. Whether the BMJ subsidy continues, ends gradually, or is replaced by subscription changes or service cuts remains unaddressed. For an organisation that spent 2024 and 2025 demanding transparency from NHS employers about pay and workforce planning, the opacity of its own restructuring is a sharp contradiction.